460 related articles for article (PubMed ID: 28389626)
21. MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.
Gao S; Liu H; Hou S; Wu L; Yang Z; Shen J; Zhou L; Zheng SS; Jiang B
Clin Transl Oncol; 2018 Jun; 20(6):703-712. PubMed ID: 29071516
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.
Okugawa Y; Toiyama Y; Toden S; Mitoma H; Nagasaka T; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
Gut; 2017 Jan; 66(1):107-117. PubMed ID: 26475630
[TBL] [Abstract][Full Text] [Related]
23. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
24. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
25. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
[TBL] [Abstract][Full Text] [Related]
26. Biomarker discovery by proteomics-based approaches for early detection and personalized medicine in colorectal cancer.
Corbo C; Cevenini A; Salvatore F
Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 28019089
[TBL] [Abstract][Full Text] [Related]
27. Serum metabolomics analysis for early detection of colorectal cancer.
Uchiyama K; Yagi N; Mizushima K; Higashimura Y; Hirai Y; Okayama T; Yoshida N; Katada K; Kamada K; Handa O; Ishikawa T; Takagi T; Konishi H; Kuriu Y; Nakanishi M; Otsuji E; Itoh Y; Naito Y
J Gastroenterol; 2017 Jun; 52(6):677-694. PubMed ID: 27650200
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma.
Kim HS; Yoon G; Do SI; Kim SJ; Kim YW
Oncotarget; 2016 Mar; 7(12):15187-99. PubMed ID: 26942563
[TBL] [Abstract][Full Text] [Related]
29. A distinct metabolic signature of human colorectal cancer with prognostic potential.
Qiu Y; Cai G; Zhou B; Li D; Zhao A; Xie G; Li H; Cai S; Xie D; Huang C; Ge W; Zhou Z; Xu LX; Jia W; Zheng S; Yen Y; Jia W
Clin Cancer Res; 2014 Apr; 20(8):2136-46. PubMed ID: 24526730
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of DHRS9 expression in colorectal cancer tissues and its prognostic significance.
Hu L; Chen HY; Han T; Yang GZ; Feng D; Qi CY; Gong H; Zhai YX; Cai QP; Gao CF
Tumour Biol; 2016 Jan; 37(1):837-45. PubMed ID: 26254099
[TBL] [Abstract][Full Text] [Related]
31. Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review.
Rasmussen SL; Krarup HB; Sunesen KG; Pedersen IS; Madsen PH; Thorlacius-Ussing O
Colorectal Dis; 2016 Jun; 18(6):549-61. PubMed ID: 26998585
[TBL] [Abstract][Full Text] [Related]
32. A high preoperative carbohydrate antigen 19-9 level is a risk factor for recurrence in stage II colorectal cancer.
Nozawa H; Ishihara S; Kawai K; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Otani K; Yasuda K; Sasaki K; Murono K; Watanabe T
Acta Oncol; 2017 May; 56(5):634-638. PubMed ID: 27885879
[TBL] [Abstract][Full Text] [Related]
33. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.
Das V; Kalita J; Pal M
Biomed Pharmacother; 2017 Mar; 87():8-19. PubMed ID: 28040600
[TBL] [Abstract][Full Text] [Related]
34. Biomarker Profile of Colorectal Cancer: Current Findings and Future Perspective.
Hoseini SH; Enayati P; Nazari M; Babakhanzadeh E; Rastgoo M; Sohrabi NB
J Gastrointest Cancer; 2024 Jun; 55(2):497-510. PubMed ID: 38168859
[TBL] [Abstract][Full Text] [Related]
35. Down-expression pattern of Ku70 and p53 coexisted in colorectal cancer.
Lu Y; Gao J; Lu Y
Med Oncol; 2015 Apr; 32(4):98. PubMed ID: 25731619
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical expression of Notch1, Jagged1, NF-κB and MMP-9 in colorectal cancer patients and the relationship to clinicopathological parameters.
Zheng CG; Chen R; Xie JB; Liu CB; Jin Z; Jin C
Cancer Biomark; 2015; 15(6):889-97. PubMed ID: 26406415
[TBL] [Abstract][Full Text] [Related]
37. Salivary metabolomics with machine learning for colorectal cancer detection.
Kuwabara H; Katsumata K; Iwabuchi A; Udo R; Tago T; Kasahara K; Mazaki J; Enomoto M; Ishizaki T; Soya R; Kaneko M; Ota S; Enomoto A; Soga T; Tomita M; Sunamura M; Tsuchida A; Sugimoto M; Nagakawa Y
Cancer Sci; 2022 Sep; 113(9):3234-3243. PubMed ID: 35754317
[TBL] [Abstract][Full Text] [Related]
38. Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinoma.
Wang XQ; Tang ZX; Yu D; Cui SJ; Jiang YH; Zhang Q; Wang J; Yang PY; Liu F
Oncotarget; 2016 Feb; 7(8):8823-38. PubMed ID: 26741506
[TBL] [Abstract][Full Text] [Related]
39. Tests and investigations for colorectal cancer screening.
Carroll MR; Seaman HE; Halloran SP
Clin Biochem; 2014 Jul; 47(10-11):921-39. PubMed ID: 24769265
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and diagnostic significance of annexin A2 in colorectal cancer.
Yang T; Peng H; Wang J; Yang J; Nice EC; Xie K; Huang C
Colorectal Dis; 2013 Jul; 15(7):e373-81. PubMed ID: 23489866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
